Creating a new type of dengue vaccine that only replicates in certain cells
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate
['FUNDING_OTHER'] · TENGEN BIOMEDICAL CO. · NIH-10553634
This study is working on a new dengue vaccine that uses a harmless version of the virus to help protect people from dengue fever without causing serious side effects, making it safer and easier to produce for everyone at risk.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TENGEN BIOMEDICAL CO. (nih funded) |
| Locations | 1 site (BETHESDA, UNITED STATES) |
| Trial ID | NIH-10553634 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel dengue vaccine that uses a replication-defective virus, which means it cannot replicate in human cells. The goal is to create a vaccine that can provide long-term protection against all four serotypes of the dengue virus without the risk of severe side effects. By using a unique approach that converts the virus to be specific to insects, the researchers aim to simplify the production process and make the vaccine safer and more effective for patients. This innovative method could lead to a more reliable vaccine option for those at risk of dengue fever.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults, particularly those living in areas where dengue fever is prevalent.
Not a fit: Patients who have already been vaccinated against dengue or those with severe allergies to vaccine components may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that protects millions from dengue fever.
How similar studies have performed: While there have been various approaches to dengue vaccine development, this specific method of using a replication-defective virus is relatively novel and has not been widely tested.
Where this research is happening
BETHESDA, UNITED STATES
- TENGEN BIOMEDICAL CO. — BETHESDA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PANG, XIAOWU — TENGEN BIOMEDICAL CO.
- Study coordinator: PANG, XIAOWU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.